Good outcomes relative to bariatric surgery after catheter ablation in observational data ...

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...

It's been a tough year for Novo Nordisk (NYSE: NVO) stock, to say the least. The company has undergone a change in CEO, its ...

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong cash runway.

Add Yahoo as a preferred source to see more of our stories on Google. Eli Lilly, which makes Zepbound and Mounjaro, just announced phase 3 clinical trial results for its new medication, retatrutide, ...

SYDNEY, AUSTRALIA - JANUARY 13: Ozempic is medicine for adults with type 2 diabetes . Wegovy is prescribed for long-term weight loss in adults and children. Both contain the active ingredient ...

Dublin, March 04, 2026 (GLOBE NEWSWIRE) -- The "GLP-1 Receptor Agonist - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for GLP-1 ...

Pharmaceutical vending machine at an airport. Image by Tim Sandle. Pharmaceutical vending machine at an airport. Image by Tim Sandle. Can a new discovery usher in a new generation of GLP-1 peptides – ...

GLP-1 receptor agonist-related agonism may prevent addiction phenotypes across all major drug classes according to authors of a recent study.

Kidney Disease,” an editorially independent special report that was produced with financial support from Vertex. M ore than one in sev ...